Earnings Releases·Nov 12, 2026, 4:05 PM ET

Assembly Biosciences — Third Quarter 2026 Earnings Summary

Collaboration revenue declined to $3.0 million in Q3 2026 from $10.8 million in the prior year period due to an $11.3 million reduction in the HPI license transaction price, while net loss widened to $20.3 million ($0.93/share) from $9.2 million ($0.72/share) year-over-year.
Cash and marketable securities decreased to $314.3 million as of September 30, 2026, from $320.4 million in June, though a $75 million collaboration extension fee received from Gilead in November 2026 is projected to fund operations into 2029.
The company initiated dosing for ABI-6250 in chronic hepatitis delta and received FDA clearance for a Phase 2 study in cholestatic liver diseases, with a Phase 2 study for GS-1179 in recurrent genital herpes expected to begin by the end of 2026.
Outstanding shares increased to 20.4 million from 15.9 million as of December 31, 2025, following the cancellation of all outstanding Class B warrants issued in August 2025 triggered by the Gilead extension fee.